SK Biopharmaceuticals has launched its epilepsy drug cenobamate in Japan through partner Ono Pharmaceutical, completing commercial launches across China, South Korea and Japan. Sold locally under the brand name Ekiscorpri, the treatment is available in four tablet strengths ranging from 12.5 milligrams to 200 milligrams for patients with partial-onset seizures. Japan is the world's second-largest single-country epilepsy market after the United States, with about 1 million patients. In an Asian Phase 3 trial involving patients from South Korea, China and Japan whose seizures were not controlled by existing antiseizure medicines, 12.4% of patients in the 100-milligram group, 30.1% in the 200-milligram group and 52.4% in the 400-milligram group achieved complete seizure freedom during the six-week maintenance period, compared with 2.6% for placebo. Dizziness and somnolence were the main adverse reactions identified during the clinical process. SK Biopharmaceuticals signed a technology export agreement with Ono in October 2020 and will earn royalty revenue linked to Japanese sales. Cenobamate is approved in about 50 countries and regions, including the United States and Europe; SK Life Science sells it directly in the U.S., while the company uses local partnerships elsewhere. President Lee Dong-hoon said the launch establishes a commercialization base in major Northeast Asian markets and that the company will pursue further growth through region-specific strategies building on its U.S. experience.